115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
    Meeting Abstract

    Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla Mercade, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer
    Meeting Abstract

    Arnold, D.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla Mercade, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Biomarkers of response and hyperprogression in patients with sarcoma treated with checkpoint blockade
    Meeting Abstract

    Klemen, N. D.; Hwang, S.; Bradic, M.; Rosenbaum, E.; Dickson, M.; Gounder, M.; Kelly, C. M.; Keohan, M. L.; Movva, S.; Thornton, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress
    Meeting Abstract

    Catenacci, D. V.; Strickler, J. H.; Shitara, K.; Nakamura, Y.; Janjigian, Y. Y.; Barzi, A.; Bekaii-Saab, T.; Lenz, H. J.; Chung, H. C.; Tabernero, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
    Meeting Abstract

    Ku, G.; Elimova, E.; Denlinger, C. S.; Mehta, R.; Lee, K. W.; Iqbal, S.; Kang, Y. K.; Oh, D. Y.; Rha, S. Y.; Kim, Y. H.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Genomic landscape of late-stage gastric cancer
    Meeting Abstract

    Janjigian, Y. Y.; Cecchini, M.; Shitara, K.; Enzinger, P. C.; Wainberg, Z. A.; Catenacci, D. V.; Chau, I.; Satoh, T.; Lee, J.; Loboda, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • EGFR inhibition in EGFR-amplified esophagogastric cancer (EGC): Retrospective global experience
    Meeting Abstract

    Maron, S.; Moya, S.; Morano, F.; Emmett, M. J.; Disel, U.; Chalasani, S.; Ku, G.; Kasi, P. M.; Uboha, N.; Kato, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Reinmuth, N.; Popat, S.; Paz-Ares, L.; Knowles, E.; Hatswell, A.; McLean, T.; Adrian, S.; Gaumond, B.; Vioix, H.; Paik, P. K.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial
    Meeting Abstract

    Peters, S.; Rizvi, N. A.; Kuziora, M.; Lai, Z.; Shrestha, Y.; Dey, A.; Barrett, J. C.; Scheuring, U.; Poole, L.; Abbosh, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)
    Meeting Abstract

    Smit, E. F. F.; Li, B. T.; Mazieres, J.; Planchard, D.; Nakagawa, K.; Goto, K.; Paz-Ares, L.; Novello, S.; Yang, J. C. H.; Ahn, M. J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save